Engage Bio
Potent, durable, and redosable non-viral genetic medicines
San Francisco , US
Synthetic Biology
Biotech
Healthcare
Therapeutics
Drug discovery
Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine.
In 2026 Engage was acquired by Eli Lilly.
- Projects
- Team
- Jobs
- News
No projects yet.
This company hasn't published any projects. Be the first to launch one!
Create Your First ProjectFounded2021
Team Size10
LocationUS
Websiteengagebio.com
🏳️
Claim This ListingIs this your company?
Claim this listing to manage your profile, add updates, and connect with your audience.